加替沙星眼药水治疗细菌性结膜炎：安全性、有效性及患者观点
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.
作者信息
Schultz Clyde
机构信息
Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada. ; Biogram Inc., Ponte Vedra, FL, USA.
出版信息
Ophthalmol Eye Dis. 2012 Jul 11;4:65-70. doi: 10.4137/OED.S7383. Print 2012.
Abstract
Gatifloxacin is a fourth generation fluroquinolone antibiotic that has been prescribed for systemic use. However, the drug which was developed by Kyorin (Japan) was linked to toxic reactions and death and was banned in the United States and Canada for use as an oral dosage form. It continues to be used as a topical application for ophthalmic conditions as the systemic toxicity seen when taking the drug orally has not been observed with ophthalmic use. The available data indicate that ocular use of gatifloxacin is safe, and effective against a broad spectrum of bacteria, including intracellular bacteria and anaerobes.
摘要
加替沙星是一种已被处方用于全身治疗的第四代氟喹诺酮类抗生素。然而，由日本杏林制药公司研发的这种药物与毒性反应及死亡有关，在美国和加拿大被禁止作为口服剂型使用。它仍被用作眼科疾病的局部用药，因为眼部使用时未观察到口服该药时出现的全身毒性。现有数据表明，眼部使用加替沙星是安全的，并且对包括细胞内细菌和厌氧菌在内的多种细菌有效。
相似文献
1
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective.加替沙星眼药水治疗细菌性结膜炎：安全性、有效性及患者观点
Ophthalmol Eye Dis. 2012 Jul 11;4:65-70. doi: 10.4137/OED.S7383. Print 2012.
2
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis.加替沙星与左氧氟沙星治疗急性细菌性结膜炎的药物治疗分析
Pak J Pharm Sci. 2018 Jul;31(4(Special)):1757-1760.
3
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.0.6%贝西沙星眼用混悬液与0.3%加替沙星滴眼液治疗新生儿细菌性结膜炎的比较
Drugs R D. 2017 Mar;17(1):167-175. doi: 10.1007/s40268-016-0164-6.
4
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.0.6%帕珠沙星滴眼液与莫西沙星 0.5%和加替沙星 0.5%治疗细菌性结膜炎的疗效和安全性：一项随机临床试验。
J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. Epub 2018 Jan 11.
5
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.莫西沙星滴眼液在治疗细菌性结膜炎中的作用。
Clin Drug Investig. 2011;31(8):543-557. doi: 10.2165/11589020-000000000-00000.
6
A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis.一项随机、研究者设盲的临床试验，比较0.3%加替沙星每日两次给药与每日四次给药治疗急性细菌性结膜炎的疗效和安全性。
Curr Med Res Opin. 2005 Mar;21(3):425-31. doi: 10.1185/030079905X30699.
7
Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.0.5%加替沙星每日给药两次，用于治疗一岁及以上患者的急性细菌性结膜炎。
J Ocul Pharmacol Ther. 2014 Dec;30(10):815-22. doi: 10.1089/jop.2014.0040.
8
Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.第四代氟喹诺酮类药物在人体房水中的渗透情况。
Ophthalmology. 2006 Jun;113(6):955-9. doi: 10.1016/j.ophtha.2006.01.061. Epub 2006 Apr 17.
9
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.第四代氟喹诺酮类眼科制剂的细菌清除率。
Adv Ther. 2009 Apr;26(4):447-54. doi: 10.1007/s12325-009-0018-5. Epub 2009 Apr 16.
10
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.0.5%莫西沙星滴眼液和0.3%加替沙星滴眼液在白内障手术患者中的眼内渗透性及生物活性
Ophthalmology. 2005 Nov;112(11):1992-6. doi: 10.1016/j.ophtha.2005.06.017. Epub 2005 Sep 23.
引用本文的文献
1
Antibacterial compounds against non-growing and intracellular bacteria.针对非生长型和细胞内细菌的抗菌化合物。
NPJ Antimicrob Resist. 2025 Apr 11;3(1):25. doi: 10.1038/s44259-025-00097-0.
2
Targeted Bacterial Keratitis Treatment with Polyethylene Glycol-Dithiothreitol-Boric Acid Hydrogel and Gatifloxacin.聚乙二醇-二硫苏糖醇-硼酸水凝胶联合加替沙星靶向治疗细菌性角膜炎。
Curr Drug Deliv. 2024;21(11):1548-1558. doi: 10.2174/0115672018279105240226050253.
3
Therapeutic potential of phage lysin PlyB in ocular infections.噬菌体溶菌酶 PlyB 在眼部感染中的治疗潜力。
mSphere. 2023 Aug 24;8(4):e0004423. doi: 10.1128/msphere.00044-23. Epub 2023 Jun 5.
4
Piperazine based antimicrobial polymers: a review.基于哌嗪的抗菌聚合物：综述
RSC Adv. 2021 Apr 23;11(25):15213-15230. doi: 10.1039/d1ra00341k. eCollection 2021 Apr 21.
5
Ultrasound-assisted gatifloxacin delivery in mouse cornea, in vivo.超声辅助在体小鼠角膜中加替沙星的传递。
Sci Rep. 2019 Oct 29;9(1):15532. doi: 10.1038/s41598-019-52069-w.
6
Bilayered films based on novel polymer derivative for improved ocular therapy of gatifloxacin.基于新型聚合物衍生物的双层薄膜用于改善加替沙星的眼部治疗。
ScientificWorldJournal. 2014 Jan 2;2014:297603. doi: 10.1155/2014/297603. eCollection 2014.
本文引用的文献
1
Antimicrobial resistance and ophthalmic antibiotics: 1-year results of a longitudinal controlled study of patients undergoing intravitreal injections.抗菌药物耐药性与眼科抗生素：接受玻璃体内注射患者的1年纵向对照研究结果
Arch Ophthalmol. 2011 Sep;129(9):1180-8. doi: 10.1001/archophthalmol.2011.213.
2
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis.加替沙星滴眼液治疗细菌性结膜炎的临床应用
Clin Ophthalmol. 2011;5:495-502. doi: 10.2147/OPTH.S13778. Epub 2011 Apr 18.
3
In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.在无苯扎氯铵和存在苯扎氯铵时，贝西沙星、莫西沙星和加替沙星的体外时效杀菌实验。
J Antimicrob Chemother. 2011 Apr;66(4):840-4. doi: 10.1093/jac/dkq531. Epub 2011 Jan 27.
4
Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK.加替沙星与泼尼松龙联合制剂用于准分子激光原位角膜磨镶术后局部预防的疗效和耐受性
Clin Ophthalmol. 2011;5:209-14. doi: 10.2147/OPTH.S17059. Epub 2011 Feb 15.
5
Microbial profile and antibiotic susceptibility of culture-positive bacterial endophthalmitis.培养阳性细菌性眼内炎的微生物谱和抗生素敏感性。
Eye (Lond). 2011 Mar;25(3):382-7; quiz 388. doi: 10.1038/eye.2010.236. Epub 2011 Feb 18.
6
Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial.抗生素单一治疗与抗生素-皮质类固醇联合治疗角膜溃疡患者的比较：双盲随机临床试验。
Can J Ophthalmol. 2011 Feb;46(1):40-5. doi: 10.3129/i10-054.
7
Sodium alginate based mucoadhesive system for gatifloxacin and its in vitro antibacterial activity.基于海藻酸钠的加替沙星粘膜粘附系统及其体外抗菌活性。
Sci Pharm. 2010 Oct-Dec;78(4):941-57. doi: 10.3797/scipharm.1004-24. Epub 2010 Sep 26.
8
Effect of fluoroquinolones on the expression of matrix metalloproteinase in debrided cornea of rats.氟喹诺酮类药物对大鼠清创角膜基质金属蛋白酶表达的影响。
Toxicol Mech Methods. 2011 Jan;21(1):6-12. doi: 10.3109/15376516.2010.529183. Epub 2010 Nov 9.
9
[Comparative research of the efficacy of the gatifloxacin and levofloxacin for bacterial conjunctivitis in human eyes].加替沙星与左氧氟沙星治疗人眼细菌性结膜炎疗效的对比研究
Zhonghua Yan Ke Za Zhi. 2010 Jun;46(6):525-31.
10
Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.比较玻璃体内庆大霉素、加替沙星和莫西沙星对兔模型角膜内皮的影响。
Jpn J Ophthalmol. 2010 Sep;54(5):481-5. doi: 10.1007/s10384-010-0838-5. Epub 2010 Nov 5.
Zotero 插件